Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway

Objectives. To evaluate the cost-effectiveness of etoricoxib (90 mg) relative to celecoxib (200/400 mg), and the nonselective NSAIDs naproxen (1000 mg) and diclofenac (150 mg) in the initial treatment of ankylosing spondylitis in Norway. Methods. A previously developed Markov state-transition model...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jansen, Jeroen P., Taylor, Stephanie D.
Format: Artigo
Idioma:Inglês
Publicat: Hindawi Publishing Corporation 2011
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3134091/
https://ncbi.nlm.nih.gov/pubmed/21772851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/160326
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars